A review and analysis of the ethical considerations in off-label ketamine use for severe, treatment-resistant depression. The review concludes that further restrictions around ketamine are not neccesary and provides a set of recomendations for oversight bodies that would support safe, effective, and ethical use.
As high-purity/high-dose ecstasy pills return to the market and casualties rise, Oli Stevens discusses the roles testing can play. It can act as a harm reduction initiative, can it shape the composition of drug markets themselves?
The ACMD has voted to keep THCv, a non-psychoactive cannabinoid with a promising properties for a range of health conditions, in Schedule 1 away from the hands of researchers.